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Abstract
Background: Adherence to Antiretroviral Therapy (ART) is critical piece in the management of HIV infected
patients. Despite the benefits of ART, non-adherence to ART persists. This study explores association between
patient’s knowledge of the ART line of treatment, availability of future treatment options and adherence.
Methods: A cross sectional survey of HIV infected adolescent and adults was conducted. Cumulative optimal
and sub-optimal adherence was defined as percentage adherence of ≥ 95 % and < 95 %, respectively. Binomial
regression models were used to assess the association of patient’s knowledge of the ART line of treatment,
availability of future treatment options and adherence.
Results: Of the 402 patients reviewed, 101 (25.1 %) patients knew their ART line of treatment and were aware that
future treatment options are limited. Compared to those who were not aware of the ART line of treatment and/or
scarcity of future treatment options, those who were aware were more likely to be adherent (adjusted prevalence
ratio [APR], 1.1; 95 % CI, 1.0–1.3).
Conclusion: The study reports knowledge of patient’s ART line of treatment and future treatment options is
important indicator of adherence to ART. Although majority of the patients did not have the knowledge, those
who had the knowledge demonstrated to be more adherent. It is critical for the physicians/health care providers
in these settings to clearly educate patients about ART line of treatment and limited availability of future treatment
options as such information is likely to influence individual behavior and improve patient’s adherence to ART.
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Background
Adherence to antiretroviral therapy (ART) is essential for
the successful management of HIV-infected patients. Clin-
ical trials and observational studies have repeatedly shown
that patients taking their prescribed medications as recom-
mended are likely to be virologically suppressed [1–3].
Despite the benefits of ARTand the known need to adhere,
non-adherence to ART persists. Recent findings indicate
that patients who were non-adherent to first line ART con-
tinued to be non-adherent to second-line ART, suggesting
that ART non-adherence is still a major concern in the
management of HIV-infected patients [4]. Furthermore, in
most resource-limited settings only two lines of ART are
available. Advances in ART-based HIV treatment and
preventive strategies such as “Treatment as Prevention”
(TasP), including prevention of mother to child transmis-
sion (PMTCT) and pre-exposure prophylaxis (PreP), have
shown promising results in preventing HIV transmission.
For example, treatment of the HIV-infected member in
sero-discordant couple reduced the risk of new HIV infec-
tions in the un-infected partner [5]; however, the success of
such strategies requires high degree of medication adher-
ence. To be virally suppressed, at least 95 % adherence is
required for a number of combined ART regimens [6] and
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for those containing boosted protease inhibitors, adherence
of at least 80 % is warranted [7, 8].
Barriers to adherence with ART have been explored
[9–11]; however, the association between a patient’s
knowledge of the ART line of treatment, awareness of
the availability of future treatment options, and adherence
to ART is lacking. Although non-adherence to ART medi-
cations may be primarily considered a personal behavioral
problem, continued support with clear understanding of
ART line of treatment as well as patient awareness of the
limited availability of treatment options may be beneficial
in improving patient ART adherence. For example, patient
awareness of the limited availability of second-line ART
following first-line ART failure may modify individual be-
havior and hence improve adherence. Due to the expenses
associated with second-line ARTas well as limited availabil-
ity of future treatment options among patients failing first-
line ART, we sought to explore the association between a
patient’s knowledge of the ART line of treatment, the avail-
ability of future treatment options, and adherence. In most
resource limited settings including Tanzania, second-line
ART is the final salvage regimen following first line failure.
It is not known if knowledge of ART line of treatment and
awareness of the limited availability of future treatment
options may be associated adherence to ART. Whether
patients who have the knowledge of the ART line of treat-
ment and are aware that future treatment options are
limited are likely to be more adherent than those without
this knowledge it is not understood. Exploring association
between knowledge of limited treatment options and
adherence is critical because such a finding will add to the
existing body of knowledge of factors associated with
adherence, and potential interventions that improve patient
adherence with ART. We explored this association using
both cross-sectional and longitudinally collected observa-
tional data from five care and treatment centers (CTC)
located within Kilimanjaro Region in Northern Tanzania.
Methods
Study design and population
We used a cross-sectional study design to evaluate the
association of knowledge of ART line of treatment, and
the limited availability of future ART treatment options,
with adherence to first-line ART. The study population
included HIV-infected adolescent and adult patients
attending CTCs at the Kilimanjaro Christian Medical
Center (KCMC), Mawenzi Regional Hospital (MRH),
Kibosho, and Kilema District Hospitals, and Majengo
Health Center in Northern Tanzania between January
2004 and May 2015. These CTCs offer treatment accord-
ing to the Tanzanian Ministry of Health treatment guide-
lines for the provision of ART. This is a secondary data
analysis involving participants who are part of the primary
study that explores predictors of viral suppression among
HIV-infected patients in those clinics. Only participants
who have been on treatment for at least 2 years in the
primary data were included.
Data collection
After obtaining informed consent, standardized ques-
tionnaires translated into Kiswahili were administered to
participating patients by trained research nurses. Among
other things, questionnaire addressed demographic char-
acteristics, knowledge of ART line of treatment, and
availability of future treatment options.
As part of routine HIV clinical care in Tanzania, all
patient data including demographics, medication use,
adherence indicators [good adherence (G) = fewer than 2
missed days per month/poor adherence (P) = 2 or more
missed days per month], were collected on standardized
forms by health care providers in those clinics and en-
tered into the National database. These standardized
forms were reviewed for an adherence assessment, and
all patients with adherence information for at least
24 months from the last clinic visit were included. Rec-
ognizing adherence wanes over time cumulative adher-
ence rating was used [12, 13]. For this study, percentage
adherence was then recalculated using 24 months of ob-
servations as the common denominator, adherence
= [number of recorded G’s/(P + G)]* 100. For example, a
person with 22 recorded G’s and two recorded P’s has an
adherence of 91.7 %. The resulting adherence percentage
was later dichotomized as optimal (adherence ≥ 95 %) or
sub-optimal (adherence < 95 %) based on previous find-
ings [6]. A near perfect adherence defined by adher-
ence ≥ 95 % is widely used for sustained viral
suppression [14]. Cumulative adherence assessment has
been used by other studies [4, 15].
Definition of variables
The primary endpoint was the cumulative percentage
adherence to first-line ART, as defined above. The expos-
ure of interest was the participant’s knowledge of ART line
of treatment, and the availability of future treatment
options. Patients were asked series of questions such as
“which line of treatment are you on?”, “can you mention
other line of treatment?” and “have you been told that
apparently second-line is the final regimen at your clinic?”
Using this information we defined knowledge on ART = 1
if participants correctly stated his/her ART line of treat-
ment (first-line or second-line) and were aware that future
treatment options were limited. Knowledge on ART was
scored as zero if participants did not know their ART line
of treatment and/or were not aware that future treatment
options were limited. We verified the ART line of treat-
ment reported by patients through a review of their med-
ical records. Other variables were evaluated including age,
gender, duration on first-line ART, treatment sites, marital
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status, education, plasma HIV RNA levels (if available),
and CD4 cell count at the time of interview.
Statistical analyses
Statistical analyses were conducted using SAS version
9.3 (SAS Institute Inc., Cary, NC). Frequencies of cat-
egorical variables were calculated as the proportions of
patients sampled. Crude and adjusted binomial regres-
sion models were used to assess the association of a pa-
tient’s knowledge of ART line of treatment, availability
of future treatment options and adherence. All associa-
tions were presented as adjusted prevalence ratios
(APRs) with 95 % confidence intervals (CIs). Estimates
whose CI crossed 1 were considered non-statistically sig-
nificant. All other variables were added into the model
and backward elimination was done with the final model
having variables whose change in estimate was ≥ 10 %.
Results
We surveyed a sample of 450 patients who were on
ART between January 2004 and May 2014. Of these, 402
(89.3 %) were on first-line ART and were used for final
analysis. Most were female (271, 67 %), and the majority
were between 30 and 55 years old (301; 75 %); (Table 1).
The greatest proportion of patients came from Mawenzi
Regional Hospital (223; 53 %). Most patients were not
aware that they were on first-line ART (321; 80 %), and
were unaware that future treatment options were limited
(317; 79 %). Approximately half of patients had been on
first-line ART for longer than 5 years (199; 50 %). The
majority had less than primary school education (332;
83 %), 199 (49.5 %), and 183 (45.5 %) were either
divorced/separated or widowed. The latest CD4+ cell
count at the time of interview was less than 350 c/mm3
for 224 (56 %) participants, and 252 (56.0 %) had HIV
RNA less than 1000c/ml.
Adherence rating
One hundred and seventy-nine participants (55.5 %) had
optimal adherence to ART. After adjusting for age,
gender, education, marital status, CD4 cell count, dur-
ation on treatment, plasma HIV RNA levels and CTC
sites, patients who knew their ART line of treatment
and were aware that future treatment options were
limited were more likely to have optimal adherence to
ART than those who had no knowledge of their ART
line of treatment and/or were unaware that future treat-
ment options were limited (prevalence ratio [PR], 1.1;
95 % CI, 1.0–1.3) (Table 2).
Several other factors were associated with ART
adherence with the estimates about the same as that of
knowledge on ART. For example, women were more likely
(APR, 1.1; (1.0–1.3) than men to have optimal adherence
to ART. Compared to patients who have been on
treatment for less than 36 months, those who have been
on treatment between 36 and 60 months were more likely
to have optimal adherence [APR, 1.2; (1.0–1.3)]. CTC site
was also positively associated with adherence to ART, and
patients from Mawenzi Regional Hospital were more likely
to have optimal adherence than those from the KCMC
Consultant Hospital (APR, 1.2; (1.0–1.4). Plasma viral load
was inversely associated with optimal adherence, as those
patients with plasma HIV RNA levels ≥ 1000 c/ml were
less likely to have optimal adherence compared to those
whose HIV-RNA < 1000 c/ml [APR, 0.8; (0.7–0.9)].
Discussion
The importance of adherence to ART cannot be overem-
phasized. The reduction of morbidity and mortality
related to HIV/AIDS and associated opportunistic infec-
tion among HIV-infected patients is clear among
patients taking their medications as prescribed [16, 17].
Interventions to improve adherence to ART are a prior-
ity, and numerous interventions have been explored [18,
19]. In this study we demonstrated that knowledge on
ART line of treatment as well as awareness of limited
availability of future treatment options is an indicator of
adherence. Patients who were aware of their ART line of
treatment and who were also informed of limited future
treatment options were 10–20 % more likely to adhere
to their medications than those who were not aware of
either. Approximately three-quarters of the study partici-
pants were not aware of their ART line of treatment
and/or did not know if future ART treatment options
are limited, reflecting a general lack of knowledge and
perspective on the use of ART regimens.
The main strengths of this study are that, to our
knowledge, it is the first study that assesses association
between patient knowledge on ART line of treatment,
future treatment options and adherence to ART. The
association between patient’s awareness of ART line of
treatment and adherence has never been explored previ-
ously and is a unique feature of this study; however,
some studies have shown associations between other
components of ART knowledge and adherence. About
80 % of HIV-infected adults in South Africa had poor
knowledge of HIV and ART, and poor medication adher-
ence was partly attributed to the poor knowledge [20].
The high proportion of patients with poor knowledge of
ART in this South African study is similar to the obser-
vations in our study. The lack of knowledge in this
setting could be factors at the patient and health care
provider level. At the patient level, high level of illiteracy
(83 % had equal to or less than primary school educa-
tion). Failure to attend ART education sessions also
explains low level of knowledge. At the provider level,
low doctor to patient ratio leads to reduced amount of
time that physicians spend with the patients [21] thereby
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limiting the amount of health education patient receives.
In addition, absence of consistent health education or
the presence of incompetent health educators who are
not fully aware of ART regimens and their availability
may explain the lack of this knowledge. Treatment
preparation is an important component in the manage-
ment of HIV patients, however, it may not be conducted
across all sites as required and if conducted, it may not
be done serially, which further may explain low levels of
patient knowledge. Similar cross sectional analyses from
Table 1 Demographic and Clinical Characteristics of HIV-Infected Patients Receiving Care at Five Care and Treatment Centers in








< 30 19 (4.7) 14 (6.3) 5 (2.8)
30–55 301 (74.9) 169 (75.8) 132 (73.7)
> 55 82 (20.4) 40 (17.9) 42 (23.5)
Gender
Male 131 (32.9) 87 (39.0) 44 (24.6)
Female 271 (67.1) 136 (61.0) 134 (75.4)
Education
≤ primary school education 332 (82.6) 188 (84.3) 144 (80.4)
> primary school education 70 (17.4) 35 (15.7) 35 (19.6)
Marital status
Not married 57 (14.1) 33 (14.8) 24 (13.4)
Married 162 (40.3) 92 (41.3) 80 (39.1)
Divorced/Separated/Widowed 183 (45.5) 98 (43.9) 75 (47.5)
CD4 at the time of interview
< 350 cells/mm3 224 (55.7) 129 (57.9) 95 (53.1)
≥ 350 cells/mm3 178 (44.3) 94 (42.1) 84 (46.9)
Duration on treatment
< 36 months 130 (32.3) 67 (30.0) 63 (35.2)
36–60 months 73 (18.2) 49 (22.0) 24 (14.4)
> 60 months 199 (49.5) 107 (48.0) 92 (51.4)
Knowledge of ART
No 301 (74.9) 158 (70.8) 143 (79.9)
Yes 101 (25.1) 65 (29.2) 36 (20.1)
Knows is on first-line ART
No 321 (79.9) 173 (77.6) 148 (82.7)
Yes 81 (20.1) 50 (22.4) 31 (17.3)
Knows other options are limited
No 317 (78.9) 168 (75.3) 149 (83.2)
Yes 85 (21.1) 55 (24.7) 30 (16.8)
Plasma HIV RNA level
< 1000 c/ml 252 (56.0) 88 (44.7) 164 (64.8)
≥ 1000 c/ml 198 (44.0) 109 (55.3) 89 (35.2)
Sites
KCMC 75 (16.7) 52 (26.4) 23 (9.1)
Mawenzi 223 (49.5) 69 (35.0) 154 (60.9)
Others 152 (33.8) 76 (38.6) 76 (30.0)
Abbreviations: KCMC Kilimanjaro Christian Medical Center, N/A Not applicable, HIV RNA Human Immunodeficiency Virus Ribonucleic Acid
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African setting reported low level of knowledge about
other component of ART some of which were associated
with poor adherent. For example,a study done in Togo
showed that only 55 % of the HIV-infected patients were
aware of the names of their prescribed ART medication
(s) [22]. Over 90 % of HIV-infected women in Ghana
had inadequate knowledge on ART, and these women
were much more likely to default from PMTC care [23].
A study of the association of knowledge on the treat-
ment plan, regimen and adherence was conducted in
Ethiopia. About 33 % had knowledge on the treatment
plan and regimen, and those who had knowledge were
more likely to be adherent than those who did not [24],
suggesting knowledge on different components of ART is
crucial in improving patient adherence. We have also been
able to show gender variations in ART adherence in that
woman tended to be more likely than men to adhere to
ART medications. A number of studies substantiated this
finding [25, 26]. In addition, recognizing adherence wanes
over time [12, 13], we used 24-month self-reported patient
information to assess cumulative adherence.
Virological outcome was also correlated with adherence
among study participants. Patients whose viral loads were
more than 1000c/ml were less likely to be adherent than
Table 2 Crude and Adjusted Risk Factors of Optimal Adherence to First-Line ART among HIV-Infected Adults Receiving Care at Five
Care and Treatment Centers in Kilimanjaro Region, Moshi, Tanzania 2004–2015
Characteristics Bivariable Analysis Prevalence
Ratio 95 % CI
Multivariable Analysis Prevalence
Ratio 95 % CI
Age
< 30 1 1
30–55 0.8 (0.6–1.0) 0.8 (0.6–1.1)
> 55 0.7 (0.5–0.9) 0.8 (0.6–1.0)
Gender
Male 1 1
Female 1.3 (1.1–1.6) 1.1 (1.0–1.3)
Education
≤ primary school education 1 1
> primary school education 0.9 (0.7–1.1) 0.9 (0.8–1.1)
Marital status
Not married 1 1
Married 1.0 (0.8–1.2) 1.0 (0.8–1.3)
Divorced/Separated/Widowed 0.9 (0.7–1.2) 1.0 (0.8–1.3)
CD4 at the time of interview
< 350 cells/mm3 1 1
≥ 350 cells/mm3 0.9 (0.8–1.1) 1.0 (0.9–1.1)
Duration on treatment
< 36 months 1 1
36–60 months 1.3 (1.0–1.6) 1.2 (1.0–1.3)
> 60 months 1.0 (0.8–1.3) 1.0 (0.9–1.2)
Knowledge of ART
No 1 1
Yes 1.2 (1.0–1.5) 1.1 (1.0–1.3)
Plasma HIV RNA level
< 1000 c/ml 1 1
≥ 1000 c/ml 0.6 (0.5–0.7) 0.8 (0.7–0.9)
Sites
KCMC 1 1
Mawenzi 1.3 (1.0–1.8) 1.2 (1.0–1.4)
Others 1.1 (0.8–1.6) 1.1 (0.9–1.4)
Abbreviations: KCMC Kilimanjaro Christian Medical Center, N/A Not applicable, HIV RNA Human Immunodeficiency Virus Ribonucleic Acid
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those whose viral loads were less than 1000c/ml, confirm-
ing the role of adherence in viral load suppression as
evidenced in multiple studies [1–3].
Our study does have a number of limitations. Although
we assessed cumulative adherence, it was from self-
reported patient information collected by health care
providers. Self-reported adherence is subject to over-
estimation of adherence percentages. Nevertheless, in this
study we were able to correlate optimal adherence with
viral load results. When the viral loads were related to
patient adherence, those with higher viral loads (≥ 1000c/
ml) were less likely to be adherent than those with low
values of viral load (< 1000 c/ml). Such a finding suggests
that our adherence percentages may have not been overes-
timated. In addition, self-reported adherence measure-
ment has been extensively used and is associated with
clinical, immunological and virological outcomes for
patients [11, 27]. In addition, with a cross-sectional study
design to assess association between knowledge of ART
and adherence, the study design cannot establish a tem-
poral association or causality. Furthermore, because we
limited patients who have been on treatment for at least
2 years from the primary data, selection bias is a potential
concern. The study might not have captured representa-
tive patients to address the research question. However,
knowledge of different components of ART has shown to
be important indicator of adherence in other studies.
Conclusion
The study reports patient knowledge of ART line of treat-
ment and future treatment options as an indicator of
adherence to ART. Although majority of the patients did
not have the knowledge, those who had the knowledge
were demonstrated to be more adherent. It is critical for
the health care providers in resource-limited settings to
clearly educate patients about ART line of treatment and
limited availability of future treatment options, and such
information may influence individual behavior and
improve patient adherence with ART.
Acknowledgments
We thank the management of the 5 CTCs for invaluable assistance in
conducting the study. We also thank study participants and other staff
members for their assistance with this study. Morevover, we thank Godfrey
Mushi, Gaudensia H. Lyimo and Rita P. Minja for conducting patient
interviews and data collection.
Funding
This research was supported by the Duke Center For AIDS Research (CFAR),
a National Institutes of Health-funded program (P30 AI064518-06).
Availability of data and materials
All data supporting our findings is contained in the manuscript. There are
no restrictions to data sources but details of the full data may be accessed
through the Principal Investigator (PI), Dr Habib Ramadhani Omari
(Kilimanjaro Christian Medical Center. Postal Address: 3010; Moshi, Tanzania.
E-mail: habibrama@gmail.com).
Authors’ contributions
HRO carried out all data analysis and prepared the manuscript as the
principle investigator. VPM was the focal person for KCMC site and
contributed to the manuscript. CM helped designing questionnaires and
assists on writing the manuscript. MO performed viral load tests and
contributed to the manuscript write up. EL was Kibosho site supervisor and
assisted with questionnaire design. JBM was Kilema supervisor and assisted
on questionnaire design. JAB was senior HIV specialist who advised on study
design and assist on manuscript write up. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Institutional Review Board approval was obtained from the Kilimanjaro
Christian Medical University College (KCMU-Co) clearance number: 277 and
Duke University Health System (DUHS) clearance number:
CR003_Pro00032975. Informed consent (written and verbal) was obtained
from the each participant prior to interviews and data collection. Informed
consent included information related to purpose of the study, potential risks
and benefits of participating, procedures of maintaining confidentiality, right
to or not to participate in this study, as well as right to withdraw from
interview at any point, were provided to the research subject.
Author details
1Kilimanjaro Christian Medical Centre (KCMC), P.O Box 3010 Moshi,
Kilimanjaro, Tanzania. 2Kilimanjaro Christian Medical University College,
Moshi, Tanzania. 3Division of Infectious Diseases and International Health,
Department of Medicine, Duke University Medical Center, Durham, NC, USA.
4Duke Global health Institute, Durham, NC, USA. 5Kilema Designated District
Hospital, Moshi, Tanzania. 6Kibosho Designated District Hospital, Moshi,
Tanzania.
Received: 1 December 2015 Accepted: 17 June 2016
References
1. Safren SA, Mayer KH, Ou SS, McCauley M, Grinsztejn B, Hosseinipour MC, et
al. Adherence to early antiretroviral therapy: results from HPTN 052, a phase
III, multinational randomized trial of ART to prevent HIV-1 sexual
transmission in serodiscordant couples. J Acquir Immune Defic Syndr.
2015;69(2):234–40.
2. Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P,
et al. Hair concentrations of antiretrovirals predict viral suppression in
HIV-infected pregnant and breastfeeding Ugandan women. AIDS
(London, England). 2015;29(7):825–30.
3. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L,
et al. Adherence to protease inhibitors, HIV-1 viral load, and development
of drug resistance in an indigent population. AIDS (London, England). 2000;
14(4):357–66.
4. Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, et
al. Association of first-line and second-line antiretroviral therapy adherence.
Open forum Infectious Dis. 2014;1(2):ofu079.
5. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC,
Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral
therapy. N Engl J Med. 2011;365(6):493–505.
6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al.
Adherence to protease inhibitor therapy and outcomes in patients with
HIV infection. Ann Intern Med. 2000;133(1):21–30.
7. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to
combination HIV antiretroviral therapy. Current HIV/AIDS Rep. 2007;4(2):65–72.
8. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al.
Not all missed doses are the same: sustained NNRTI treatment interruptions
predict HIV rebound at low-to-moderate adherence levels.
PLoS One. 2008;3(7):e2783.
9. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, Suleh A, et
al. Payment for antiretroviral drugs is associated with a higher rate of
Ramadhani et al. BMC Health Services Research  (2016) 16:265 Page 6 of 7
patients lost to follow-up than those offered free-of-charge therapy in
Nairobi, Kenya. Trans R Soc Trop Med Hyg. 2008;102(3):288–93.
10. Senkomago V, Guwatudde D, Breda M, Khoshnood K. Barriers to
antiretroviral adherence in HIV-positive patients receiving free medication
in Kayunga, Uganda. AIDS care. 2011;23(10):1246–53.
11. Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL,
et al. Predictors of incomplete adherence, virologic failure, and antiviral
drug resistance among HIV-infected adults receiving antiretroviral therapy
in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.
12. Mbonye M, Seeley J, Ssembajja F, Birungi J, Jaffar S. Adherence to
antiretroviral therapy in Jinja, Uganda: a Six-year follow-Up study.
PLoS One. 2013;8(10):e78243.
13. Wilson IB, Bangsberg DR, Shen J, Simoni JM, Reynolds NR, Goggin K, et al.
Heterogeneity among studies in rates of decline of ART adherence over
time: results from the MACH14 study. J Acquir Immune Defic Syndr.
2013;64:448–54.
14. Bangsberg DR. Less than 95 % adherence to nonnucleoside reverse-
transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis.
2006;43(7):939–41.
15. El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, et al.
Adherence to drug-refill is a useful early warning indicator of virologic and
immunologic failure among HIV patients on first-line ART in South Africa.
PLoS One. 2011;6(3):e17518.
16. Slaymaker E, Todd J, Marston M, Calvert C, Michael D, Nakiyingi-Miiro J, et al.
How have ART treatment programmes changed the patterns of excess
mortality in people living with HIV? Estimates from four countries in East
and Southern Africa. Glob Health Action. 2014;7:22789.
17. Kanjala C, Michael D, Todd J, Slaymaker E, Calvert C, Isingo R, et al. Using
HIV-attributable mortality to assess the impact of antiretroviral therapy on
adult mortality in rural Tanzania. Glob Health Action. 2014;7:21865.
18. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et
al. Guidelines for improving entry into and retention in care and
antiretroviral adherence for persons with HIV: evidence-based
recommendations from an international association of physicians in AIDS
care panel. Ann Intern Med. 2012;156(11):817–294.
19. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell ML.
Interventions to increase antiretroviral adherence in sub-Saharan Africa: a
systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942–51.
20. Terblanche LM, Stellenberg EL. Patient knowledge of HIV and its treatment
in South Africa. African J Prim Health care Family Med. 2014;6(1):E1–7.
21. http://www.intrahealth.org/page/tanzania Accessed 20 Apr 2016.
22. Potchoo Y, Tchamdja K, Balogou A, Pitche VP, Guissou IP, Kassang EK.
Knowledge and adherence to antiretroviral therapy among adult people
living with HIV/AIDS treated in the health care centers of the association
“Espoir Vie Togo” in Togo, West Africa. BMC Clin Pharmacol. 2010;10:11.
23. Boateng D, Kwapong GD, Agyei-Baffour P. Knowledge, perception about
antiretroviral therapy (ART) and prevention of mother-to-child-transmission
(PMTCT) and adherence to ART among HIV positive women in the Ashanti
Region, Ghana: a cross-sectional study. BMC Womens Health. 2013;13:2.
24. Demessie R, Mekonnen A, Amogne W, Shibeshi W. Knowledge and
adherence to antiretroviral therapy among adult people living with HIV/
AIDS at Tikur Anbessa Specialized Hospital, Ethiopia. Int J Basic Clin
Pharmacol. 2014;3(2):320–30.
25. Wasti SP, Simkhada P, Randall J, Freeman JV, van Teijlingen E.
Factors influencing adherence to antiretroviral treatment in Nepal:
a mixed-methods study. PLoS One. 2012;7(5):e35547.
26. Sasaki Y, Kakimoto K, Dube C, Sikazwe I, Moyo C, Syakantu G, et al.
Adherence to antiretroviral therapy (ART) during the early months of
treatment in rural Zambia: influence of demographic characteristics and
social surroundings of patients. Ann Clin Microbiol Antimicrob. 2012;11:34.
27. Gare J, Kelly-Hanku A, Ryan CE, David M, Kaima P, Imara U, et al. Factors
influencing antiretroviral adherence and virological outcomes in people
living with HIV in the highlands of Papua New Guinea. PLoS One. 2015;
10(8):e0134918.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ramadhani et al. BMC Health Services Research  (2016) 16:265 Page 7 of 7
